Opdivo-Yervoy (nivolumab-ipilimumab)
pCPA File Number:
23063
Negotiation Status:
Active Negotiation
Indication(s):
In neoadjuvant setting for resectable stage III melanoma.
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PX0371-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable